FIELD: medicine; pulmonology.
SUBSTANCE: invention can be used to diagnose cold airway hyperreactivity in patients with bronchial asthma without conducting a bronchoprovocation test with isocapnic hyperventilation. Two questionnaires are completed — the Asthma Control Test and the Cold Sensitivity Screening Questionnaire, scoring responses. The sum of points is calculated in each questionnaire separately. Then the change in forced expiratory volume for the first second before and after aerosol inhalationβ2-short-acting agonist is determined. Diagnostics is carried out by comparing the value of the discriminant function (D), calculated using a given equation, with the boundary value of the discriminant function equal to +95.87. When D is equal to or greater than the limit value, the presence of cold airway hyperreactivity in a patient with bronchial asthma is diagnosed, when D is less than the limit value of the discriminant function, the absence of cold airway hyperreactivity in a patient with bronchial asthma is diagnosed.
EFFECT: method makes it possible to achieve better control over the disease by applying a personal approach to prescribing drug anti-inflammatory therapy due to the possibility of verifying cold airway hyperreactivity at the outpatient stage in patients with asthma without performing a bronchoprovocation IHCI test.
1 cl, 6 tbl, 2 ex
